In announcing its fourth-quarter earnings Tuesday, Boston Scientific (NYSE:BSX) also announced that it was reducing its workforce by 900 to 1,000 people worldwide, a move that will lower pre-tax operating expenses by $100 million to $115 million by the end of the year. The reduction will occur through a mixture of attrition and layoffs. A […]
It’s not great when a company needs a rival to have a major disaster in order to see the upside, but when you are Boston Scientific (NYSE: BSX), it may be welcome news indeed. That is the queer situation Boston Scientific finds itself in at the close of a tough year. Or at least that […]
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
UPDATED WITH ANALYST COMMENT Boston Scientific (NYSE:BSX) is jumping on the renal denervation bandwagon. The Natick, Massachusetts, medical device manufacturer announced Thursday that it is buying Caifornia startup Vessix Vascular for an upfront payment of $125 million and the prospect of additional milestone payments between 2013 and 2019 that would make the transaction be […]
On Wednesday, after Boston Scientific (NYSE:BSX) announced the acquisition of Minnesota startup BridgePoint Medical, the startup’s CEO said that he is excited by the prospect of having the company’s technology marketed by Boston Scientific’s sales and marketing operation. Describing Boston Scientific as the “leader” in the interventional cardiology field and the cath lab, Denis Harrington […]
If Boston Scientific (NYSE: BSX) were to break up its cardiac rhythm management business into a cardiac unit and an interventional cardiology unit as Reuters reported, the move will spell the recognition that an integrated sales force could not bring about lowered selling costs without an accompanying loss in revenue. That is the opinion of […]
For the last year, Boston Scientific’s (NYSE:BSX) stock has hovered between $5 and $6, and no amount of share buybacks have nudged the price up much. In the company’s second-quarter earnings call last week, analyst Michael Weinstein of JP Morgan asked chief financial officer Jeffrey Capello whether repurchasing shares was the best use of Boston Scientific’s […]
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
If people are looking for confirmation that the global cardiac rhythm management market has declined as much as it could and will fall no further, they have to wait a while. A week ago St. Jude Medical CEO Dan Starks admitted that the company has been routinely too optimistic in predicting the bottom of the […]
Boston Scientific announced Monday that it is collaborating with Royal Philips Electronics through which the Dutch company will sell Boston Scientific Imaging equipment compatible with its imaging systems globally. Specifically, the marketing and distribution agreement relates to Boston Scientific’s iLabs ultrasound imaging system and its imaging catheters, which will now be sold with Philips’ Allura Xper […]
Boston Scientific (NYSE:BSX) announced late Wednesday that the U.S. Food and Drug Administration has approved two drug-coated stent systems for heart attack patients. These are the first stents in the world to be cleared for patients suffering from the symptoms of acute myocardial infarction (AMI) or heart attack. The stents are the Ion and […]
A look at how Boston Scientific has shaped the emerging med tech landscape, and where the ex-BSC-ers are making their impact now.
As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.
Paulson & Co. Inc. is Boston Scientific Corp.’s (NYSE:BSX) largest shareholder no more, after liquidating its position in BSX completely by selling off some 15 million shares of the Natick, Mass.-based medical device company during the second quarter. The New York-based fund has been steadily selling off its BSX shares for more than a year. […]
The cardiac rhythm management industry looks like it needs of a jolt of its own, badly. A look at the earnings releases of two of the big three players in the CRM Market, Boston Scientific (NYSE:BSX) and St. Jude Medical (NYSE:STJ), reveals that the slump in the cardiac rhythm management business is more persistent than […]
Shares of Boston Scientific Corp. (NYSE:BSX) traded at unusually high volumes for two straight weeks during the recent roller coast on Wall Street, coming in at more than 120 million trades during the week ending July 29 and topping 140 million the week ending August 5. Last week shaped up to top even those numbers, […]
Boston Scientific Corp. (NYSE:BSX) plans to spend $37 million on overseas research and development, this time at its R&D facility in Clonmel, Ireland. The Natick, Mass.-based company hopes to jump-start development of a next generation cardiac rhythm management system. The funding is partially supported by a grant from IDA Ireland, a quasi-public investment promotion agency, […]
In the stockapocalypse that was Manic Monday, medical technology and pharma stocks got a mere slap on the wrist compared with banking stocks that received a more humiliating pants-down whipping. It appears that pharma stocks fared better than medical device and biotech stocks. GlaxoSmithKline (NYSE:GSK) was down a mere 28 cents to close at $39.44 […]